🟢 Alzamend Neuro is trading 5% up in pre-market with no fresh catalyst identified

Alzamend Neuro is trading 5.03% higher at $1.53, with no new company-specific announcement identified to explain the November 4 pre-market move.

• Shares gained 16.80% to $1.46 at the November 3 close and have risen over several recent sessions.
• The latest company releases listed on its investor-relations site predate the November 3 session. A November 14–18 neuroscience meeting features a previously announced company presentation.
• Available evidence does not establish a direct link to broader market strength.